FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134767464> ?p ?o ?g. }

• W3134767464 endingPage "102869" @default.
• W3134767464 startingPage "102869" @default.
• W3134767464 abstract "<h2>ABSTRACT</h2><h3>Background</h3> : Neuromyelitis Optica spectrum disorder (NMOSD) is an inflammatory disease, which manifests mostly as recurrent episodes of optic neuritis or myelitis that cause important disability. Early diagnosis and prompt initiation of immunosuppressive therapy are crucial in reducing relapses, disability, and mortality. Even though, there are few prospective randomized controlled trials, several drugs have proved to be both effective and safe. Azathioprine and Rituximab represent the standard of care and are used as first-line treatment agents worldwide. However, recent studies have unveiled new therapies, such as monoclonal antibodies. To make treatment recommendations and management guidelines, it is imperative to define an appropriate standard of care. <h3>Methods</h3> : A systematic literature review was performed in MEDLINE, EMBASE, and LILACS databases using the following terms: (NMO OR Devic OR Neuromyelitis Optica) AND (Azathioprine OR Prednisone OR Rituximab OR Tocilizumab OR Bortezomib OR Inebilizumab OR Eculizumab OR Satralizumab) including both, randomized clinical trials and observational studies published between January 2006 and January 2021. The inclusion criteria comprised patients aged 18 or older, NMOSD diagnosis following the Wingerchuck criteria, two or more therapies been compared, and the evaluation of both efficacy and safety outcomes. All studies comparing treatment only with placebo were excluded. Quality was assessed according with the design of the study, and results were synthesized through comparative tables for each outcome evaluated, differentiating the results of randomized and non-randomized studies. <h3>Results</h3> : Thirteen studies with 1447 patients were included. Twelve studies evaluated the expanded disability status scale (EDSS) before and after treatment; in five of seven evaluating rituximab, it outperformed its comparators in improving the disability degree. Eleven studies assessed the annual relapse rate (ARR). Again, in six of seven evaluating rituximab, it was superior to other therapies. Time to relapse (TTR) was reported in five studies. The three studies that included Rituximab revealed a longer time to relapse in this arm of treatment. Finding were consistent in randomized and non-randomized studies. The new molecules Satralizumab, Eculizumab and Tocilizumab were evaluated in one study each, proving to be highly effective and safe. The safety profile analysis showed a higher number of adverse events for Azathioprine. <h3>Discussion</h3> : This systematic review demonstrates a superiority tendency of Rituximab upon the other treatments strengthening the available evidence about NMOSD management. Superiority in EDSS outcomes, annual relapse rate, time to first relapse and relapses during treatment time was evidenced in the Rituximab group compared to other medications, with lower rates of adverse events. New molecules Tocilizumab, Eculizumab and Satralizumab also showed superiority in the evaluated results, especially in the relapses during treatment time outcome, although with subtle differences in EDSS and ARR outcomes. <h3>Conclusion</h3> : Our results suggest that monoclonal antibodies are highly effective and safe for the treatment of NMOSD; Rituximab showed better performance on multiple outcomes and has more evidence available. New molecules: Eculizumab, Tocilizumab, Satralizumab are good options for treatment. Drugs like Azathioprine and Mycophenolate are effective, but with a worse risk-benefit ratio, therefore, they are useful alternatives in places that do not have access to monoclonal antibodies." @default.
• W3134767464 created "2021-03-15" @default.
• W3134767464 creator A5028454185 @default.
• W3134767464 creator A5031954706 @default.
• W3134767464 creator A5036961669 @default.
• W3134767464 creator A5041490776 @default.
• W3134767464 creator A5055759051 @default.
• W3134767464 creator A5068900168 @default.
• W3134767464 date "2021-05-01" @default.
• W3134767464 modified "2023-10-17" @default.
• W3134767464 title "Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature." @default.
• W3134767464 cites W1988435452 @default.
• W3134767464 cites W2009114633 @default.
• W3134767464 cites W2013278685 @default.
• W3134767464 cites W2014893669 @default.
• W3134767464 cites W2038941725 @default.
• W3134767464 cites W2062040186 @default.
• W3134767464 cites W2089363506 @default.
• W3134767464 cites W2100093402 @default.
• W3134767464 cites W2129229339 @default.
• W3134767464 cites W2136132690 @default.
• W3134767464 cites W2296419904 @default.
• W3134767464 cites W2522644963 @default.
• W3134767464 cites W2540565392 @default.
• W3134767464 cites W2617254659 @default.
• W3134767464 cites W2625404774 @default.
• W3134767464 cites W2747029006 @default.
• W3134767464 cites W2778216211 @default.
• W3134767464 cites W2943416206 @default.
• W3134767464 cites W2963439432 @default.
• W3134767464 cites W2972221943 @default.
• W3134767464 cites W2989992495 @default.
• W3134767464 cites W2991438804 @default.
• W3134767464 cites W2997518134 @default.
• W3134767464 cites W3005681385 @default.
• W3134767464 cites W3012054652 @default.
• W3134767464 cites W3018886418 @default.
• W3134767464 cites W3019956952 @default.
• W3134767464 doi "https://doi.org/10.1016/j.msard.2021.102869" @default.
• W3134767464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33711580" @default.
• W3134767464 hasPublicationYear "2021" @default.
• W3134767464 type Work @default.
• W3134767464 sameAs 3134767464 @default.
• W3134767464 citedByCount "15" @default.
• W3134767464 countsByYear W31347674642022 @default.
• W3134767464 countsByYear W31347674642023 @default.
• W3134767464 crossrefType "journal-article" @default.
• W3134767464 hasAuthorship W3134767464A5028454185 @default.
• W3134767464 hasAuthorship W3134767464A5031954706 @default.
• W3134767464 hasAuthorship W3134767464A5036961669 @default.
• W3134767464 hasAuthorship W3134767464A5041490776 @default.
• W3134767464 hasAuthorship W3134767464A5055759051 @default.
• W3134767464 hasAuthorship W3134767464A5068900168 @default.
• W3134767464 hasConcept C126322002 @default.
• W3134767464 hasConcept C168563851 @default.
• W3134767464 hasConcept C177713679 @default.
• W3134767464 hasConcept C187212893 @default.
• W3134767464 hasConcept C203014093 @default.
• W3134767464 hasConcept C2776760755 @default.
• W3134767464 hasConcept C2777178219 @default.
• W3134767464 hasConcept C2779134260 @default.
• W3134767464 hasConcept C2779338263 @default.
• W3134767464 hasConcept C2780640218 @default.
• W3134767464 hasConcept C2780653079 @default.
• W3134767464 hasConcept C2780892749 @default.
• W3134767464 hasConcept C2781004633 @default.
• W3134767464 hasConcept C2781137167 @default.
• W3134767464 hasConcept C71924100 @default.
• W3134767464 hasConceptScore W3134767464C126322002 @default.
• W3134767464 hasConceptScore W3134767464C168563851 @default.
• W3134767464 hasConceptScore W3134767464C177713679 @default.
• W3134767464 hasConceptScore W3134767464C187212893 @default.
• W3134767464 hasConceptScore W3134767464C203014093 @default.
• W3134767464 hasConceptScore W3134767464C2776760755 @default.
• W3134767464 hasConceptScore W3134767464C2777178219 @default.
• W3134767464 hasConceptScore W3134767464C2779134260 @default.
• W3134767464 hasConceptScore W3134767464C2779338263 @default.
• W3134767464 hasConceptScore W3134767464C2780640218 @default.
• W3134767464 hasConceptScore W3134767464C2780653079 @default.
• W3134767464 hasConceptScore W3134767464C2780892749 @default.
• W3134767464 hasConceptScore W3134767464C2781004633 @default.
• W3134767464 hasConceptScore W3134767464C2781137167 @default.
• W3134767464 hasConceptScore W3134767464C71924100 @default.
• W3134767464 hasLocation W31347674641 @default.
• W3134767464 hasOpenAccess W3134767464 @default.
• W3134767464 hasPrimaryLocation W31347674641 @default.
• W3134767464 hasRelatedWork W2177846153 @default.
• W3134767464 hasRelatedWork W2337201674 @default.
• W3134767464 hasRelatedWork W2522065455 @default.
• W3134767464 hasRelatedWork W2625404774 @default.
• W3134767464 hasRelatedWork W3090055250 @default.
• W3134767464 hasRelatedWork W3113951574 @default.
• W3134767464 hasRelatedWork W3134767464 @default.
• W3134767464 hasRelatedWork W3183852848 @default.
• W3134767464 hasRelatedWork W3211105349 @default.
• W3134767464 hasRelatedWork W66911304 @default.
• W3134767464 hasVolume "50" @default.
• W3134767464 isParatext "false" @default.

• next